Colorectal Cancer

Your daily dose of the clinical news you may have missed.

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

Only about 75% of people with a positive result on a stool-based test for colorectal cancer complete screening with a colonoscopy. Fendrick "won't rest" until it's 90%.

Mark Fendrick, MD, thinks that right now, the relative accuracy of blood-based tests for CRC compared with available alternatives is not quite comparable. He explains.

With a population goal of having 80% to 90% of age-eligible Americans screened for colorectal cancer, colonoscopy can not be the initial test for everyone, Fendrick emphasizes.

Never considered the carbon footprint left by a screening for colorectal cancer? Fendrick has and did the research to learn more. He explains in this short video.

GLP-1 receptor agonists showed promise in lowering obesity-related cancer risks in adults with type 2 diabetes, particularly colorectal cancer.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The increase in stool-based CRC testing is a logical trend, Hendrick said in an interview, given the convenience plus the 2 million younger adults now eligible for screening.

DDW 2025. Follow-up colonoscopy after a positive stool-based test was superior among adults aged 45-49 and across diverse populations whose original test was mt-sDNA.

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.

GRAIL announced plans to present new support for the Galleri test's ability to simultaneously screen for multiple cancers plus its accuracy for cancer signal of origin prediction.

The increase in pancreatic cancer among Americans aged 15 to 34 is particularly alarming and should alert clinicians to heed relevant GI symptoms as suspicious.

The phone-based patient navigation intervention addressed barriers to CRC testing follow-up and included patient education.

Myths and fears about cancer screening may be keeping some of your patients from important tests. Always ask about misconceptions, and then offer the facts.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The model identified BMI, tobacco use, and family history of CRC as the strongest predictors for advanced neoplasia in young adults.

Adding a deadline to a mailed invitation for FIT colorectal cancer screening resulted in improved return rates, according to new research.

New AGA guidelines conclude that it is not clear whether computer-aided detection systems for colonoscopy should be recommended for routine widespread use.

Cervical cancer screening rates remained below prepandemic levels, while rates for breast and colorectal cancers rebounded from pandemic declines.

New evidence-based guidance for bowel prep considers patient preference and history and updates timing of prep regimen, dietary restrictions, and follow-up recommendations.

The outsized burden continues among Black men, a group with prostate cancer incidence rates 67% higher than those of White men and mortality rates more than twice as high.

A family medicine specialist who works with cancer survivorship highlights findings of a study that illustrate how effective screening is and how treatment has changed.

World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.

Your daily dose of the clinical news you may have missed.

ASCO GI Cancers Symposium: The Freenome blood-based test identified nearly 80% of individuals who had colorectal cancer.

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.